•The FDA approved KEYTRUDA and KEYTRUDA QLEX, each in combination with WELIREG, for the adjuvant treatment of patients with clear cell renal cell carcinoma.
•The US FDA approved AstraZeneca's TRUQAP (capivasertib) as the first targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer.
•Horizon Space Acquisition II announced the closing of its business combination with SL BIO to form SL Science Holding, trading as SLBT from June 15, 2026.
•Momentus Inc. shares dropped 26.69% to $11.95 on heavy trading volume exceeding 10 million shares.
•Astrotech, Destiny Tech100, and the SATG ETF saw declines driven by sector volatility and profit-taking.
•MicroVision applied to transfer its listing from The Nasdaq Global Market to The Nasdaq Capital Market to seek an additional 180-day compliance period for the minimum bid price requirement.
•The company announced it will host a business update and interactive shareholder Q&A session on June 25, 2026.
•The company filed a new Form S-3 registration statement to replace an expiring shelf registration statement.
•Norsk Hydro declared a second force majeure on aluminium sales from Qatar following an unexpected termination of a marketing agreement by the Qatalum joint venture.
•The Indian government is preparing to allow the budget deficit to widen to 4.8% of GDP for the current fiscal year, exceeding the previous 4.3% target.
•India’s Finance Ministry reassured credit rating agencies that the fiscal deterioration is due to external geopolitical pressures rather than policy changes.